NEUROINFLAMMATION IN NEURONAL DEATH AND REPAIR

Bagetta, Giacinto

In stock
Regular price 88.750 KD inc. VAT
License
Table of contents
  • Contentsv
  • Contributorsv
  • Prefacev
  • Forewordv
  • Chapter 1: Inflammatory Mediators Leading to Protein Misfolding and Uncompetitive/Fast Off-Rate Drug1
  • I. Introduction3
  • II. Protein Misfolding in Neurodegenerative Diseases5
  • III. Generation of RNS/ROS6
  • IV. Protein S-Nitrosylation and Neuronal Cell Death7
  • V. Parkin and the UPS9
  • VI. S-Nitrosylation and Parkin10
  • VII. The Unfolded Protein Response and PDI11
  • VIII. S-Nitrosylation of PDI Mediates Protein Misfolding and Neurotoxicity in Cell Models of PD or A14
  • IX. PDI Activity in ALS and Prion Disease15
  • X. Potential Treatment of Excessive NMDA-Induced Ca2+ Influx and S-Nitrosylation16
  • XI. Looking to the Future: NitroMemantines18
  • XII. Conclusions19
  • Acknowledgments20
  • References20
  • Chapter 2: Innate Immunity and Protective Neuroinflammation: New Emphasis on the Role of Neuroimmune29
  • I. Characteristics of the Cellular and Molecular Innate Immune Responses in the Brain30
  • II. Innate Immune Response in Health: The Key Role of Physical Barriers32
  • III. Immunoprivileged Status of the Brain by Preventing the Infiltration of Potentially Harmful Syst33
  • IV. Protective Innate Immune Response During Brain Infection and Inflammation to Promote the Clearan35
  • V. Interactions of Innate Immune Molecules with Toxic Proteins: Roles of PPAMPs36
  • VI. Regulating the Innate Immune Response in the CNS While Promoting Tissue Repair: Roles of Neuroim38
  • VII. Innate Immunity and Neurogenesis42
  • VIII. The Canonical Innate Immune System in the CNS: The Complement System43
  • IX. Conclusion: Elements to Drive Innate Immune Neuroprotective Activities45
  • Glossary46
  • References47
  • Chapter 3: Glutamate Release from Astrocytes in Physiological Conditions and in Neurodegenerative Di57
  • I. Introduction58
  • II. Ca2+-Dependent Glutamate Release from Astrocytes59
  • III. Excitotoxicity Involving Ca2+-Dependent Glutamate Release from Astrocytes in Pathological Condi62
  • IV. Astrocytic Alterations and Ca2+-Dependent Glutamate Release Dysfunction in AD65
  • V. Conclusions67
  • References68
  • Chapter 4: The High-Mobility Group Box 1 Cytokine Induces Transporter-Mediated Release of Glutamate73
  • I. Introduction74
  • II. Gliosomes as a Model to Study Astrocyte Characteristics75
  • A. Characterization of the Gliosome Preparation75
  • B. Glutamate Release in Gliosomes78
  • C. Expression of Proteins of the Release Machinery in Gliosomes79
  • III. HMGB1-Induced Glutamate Release from Gliosomes81
  • A. Cytokine Properties of HMGB181
  • B. Effect of HMGB1 on Glutamate Release from Gliosomes and Synaptosomes84
  • C. Mechanisms of the HMGB1-Induced Release of Glutamate from Gliosomes84
  • D. HMGB1 Binding to Gliosomes85
  • IV. Concluding Remarks88
  • Acknowledgments89
  • References90
  • Chapter 5: The Role of Astrocytes and Complement System in Neural Plasticity95
  • I. Introduction96
  • II. Astrocytes, GFAP, and Astrocyte Intermediate Filaments96
  • III. Reactive Gliosis, Neurotrauma, and CNS Transplants100
  • IV. The Complement System103
  • Acknowledgments106
  • References107
  • Chapter 6: New Insights into the Roles of Metalloproteinases in Neurodegeneration and Neuroprotectio113
  • I. Introduction114
  • II. The NEP Family115
  • III. The NEP Homologue ECE-1121
  • IV. The ACE Family123
  • V. Ischemia/Hypoxia and Ageing as Factors Affecting Metalloproteinases125
  • VI. Conclusions127
  • References128
  • Chapter 7: Relevance of High-Mobility Group Protein Box 1 to Neurodegeneration137
  • I. Introduction137
  • II. Structure and Nuclear Functions139
  • III. Cytokine Functions140
  • IV. Role of HMGB1 in CNS (DYS)Function142
  • V. Conclusions145
  • References145
  • Chapter 8: Early Upregulation of Matrix Metalloproteinases Following Reperfusion Triggers Neuroinfla149
  • I. Introduction150
  • II. Methods152
  • A. Focal Cerebral Ischemia and Drug Treatments152
  • B. Neuropathology and Quantification of Ischemic Damage153
  • C. IL-1 beta ELISA153
  • D. Western Blotting153
  • E. In Situ Zymography154
  • F. Gel Zymography154
  • G. Fluorimetric Caspase-1 Activity Assay155
  • H. Statistical Analysis156
  • III. Results156
  • IV. Discussion161
  • Acknowledgments164
  • References164
  • Chapter 9: The (Endo)Cannabinoid System in Multiple Sclerosis and Amyotrophic Lateral Sclerosis171
  • I. Introduction172
  • II. The ECS172
  • III. ECS in MS173
  • A. Interplay Between Inflammatory Process and Cannabinoids in MS174
  • B. Interplay Between Neurodegeneration Mechanisms and Cannabinoids in MS175
  • IV. ECS in ALS176
  • A. Interplay Between Glutamate Transmission and Endocannabinoids in ALS177
  • B. Interplay between Oxidative Stress and Endocannabinoids in ALS178
  • C. Interplay Between Microglial Activation and Endocannabinoids in ALS178
  • D. Interplay Between Inflammatory Mediators and Endocannabinoids in ALS179
  • V. Conclusions179
  • Acknowledgments180
  • References180
  • Chapter 10: Chemokines and Chemokine Receptors: Multipurpose Players in Neuroinflammation187
  • I. Introduction188
  • A. The Chemokine System Plays an Essential Role in Leukocyte Trafficking and Immunity188
  • B. Chemokines Regulate Cell-Cell Interactions188
  • C. Nonsignaling Chemokine "Interceptors" Help Localize Chemokines Within Tissue189
  • D. On Beyond Immunity: Chemokines Regulate Development and Physiology of the Nervous System189
  • E. Chemokines are Selective Leukocyte Chemoattractants in EAE and are Implicated in Disease Pathogen190
  • II. Fractalkine and Fractalkine Receptor (CX3CR1) Govern Regulatory NK Accumulation and Microglial A191
  • A. Fractalkine is Essential for Accumulation of Regulatory NK Cells in the Inflamed CNS During EAE191
  • B. CX3CR1 is a Critical Inhibitor of Microglial Neurotoxicity194
  • III. CXCR2 Regulates Both Monocyte Infiltration and Oligodendrocyte-Mediated Tissue Repair in EAE197
  • A. CXCL1 Acts Through CXCR2 to Arrest Migrating OPCs197
  • B. EAE in CXCR2-/- Mice: CXCR2 Deficiency Dramatically Reduces Susceptibility to EAE198
  • References201
  • Chapter 11: Systemic and Acquired Immune Responses in Alzheimer's Disease205
  • I. Alzheimer's Neuropathology205
  • II. Cellular Immune Responses206
  • A. Lymphocytes216
  • B. Monocytes/Macrophages217
  • C. Molecular Profiles of Peripheral Immune Cells218
  • III. Humoral Immune Responses in the Periphery218
  • A. Antibodies219
  • B. Complement220
  • C. Cytokines and Related Proteins221
  • IV. Conclusion223
  • Acknowledgments223
  • References223
  • Chapter 12: Neuroinflammation in Alzheimer's Disease and Parkinson's Disease: Are Microglia Pathogen235
  • I. Introduction236
  • II. Neuroinflammation in AD and PD237
  • III. PD May Provide a More Facile Model for Demonstrating a Pathogenic Role of Neuroinflammation237
  • IV. Advantages of Microglial Cell Cultures238
  • V. Responses of Cultured Microglia to AD and PD Pathology239
  • VI. Conclusions241
  • References244
  • Chapter 13: Cytokines and Neuronal Ion Channels in Health and Disease247
  • I. Introduction247
  • II. Properties of Ion Channels251
  • III. Distribution and Targeting of Neuronal Ion Channels251
  • IV. Ion Channels Are Targeted by Proinflammatory Cytokines252
  • V. IL-1beta and Voltage-Dependent Ca2+ Channels254
  • VI. IL-1beta and NMDAR256
  • VII. TNF-alpha: Few Final Considerations258
  • VIII. Conclusions258
  • References259
  • Chapter 14: Cyclooxygenase-2, Prostaglandin E2, and Microglial Activation in Prion Diseases265
  • I. Introduction266
  • II. COXs and PGs in Brain Functions267
  • III. Prion Diseases268
  • IV. COXs in Human and Experimental Prion Diseases270
  • V. Roles of COX-2 and PGE2 in Prion Diseases272
  • Acknowledgments273
  • References273
  • Chapter 15: Glia Proinflammatory Cytokine Upregulation as a Therapeutic Target for Neurodegenerative277
  • I. Neuroinflammation and Disease Progression278
  • II. CNS Proinflammatory Cytokine Production as a Therapeutic Target for AD280
  • A. Protein Phosphorylation Pathways as Regulators of Proinflammatory Cytokine Production281
  • B. The p38 MAPK as a Therapeutic Target for AD284
  • III. De Novo Lead Compound Discovery and the Recent Major Changes in Translational Research at the C285
  • IV. Development of Minozac: A Function-Driven Approach to Develop Small Molecule Compounds That Targ288
  • Acknowledgments292
  • References292
  • Chapter 16: Oxidative Stress and the Pathogenesis of Neurodegenerative Disorders297
  • I. Introduction: Free Radicals, Immunity, and the Nervous System298
  • II. Neuropathogenesis of Neurodegeneration301
  • III. Free Radicals and Neurodegenerative Disorders306
  • IV. Glutathione System, Glutamate-Glutamine Cycle, and the CNS308
  • V. Modulators of Microglial Activation309
  • VI. Growth Factors, Antioxidants, and Anti-Inflammatory Drug Therapies313
  • VII. Therapeutic Immunomodulation315
  • VIII. Summary317
  • Acknowledgments317
  • References317
  • Chapter 17: Differential Modulation of Type 1 and Type 2 Cannabinoid Receptors along the Neuroimmune327
  • I. Introduction328
  • II. Lipid Rafts and Cannabinoid Receptors328
  • III. Discussion331
  • Acknowledgments334
  • References334
  • Chapter 18: Effects of the HIV-1 Viral Protein TAT on Central Neurotransmission: Role of Group I Met339
  • I. Neurological Complications of HIV-1 Infection340
  • II. The HIV-1 Viral Protein Tat341
  • III. About the Experimental Approach342
  • IV. Effects of Tat on the Release of Neurotransmitters in CNS342
  • V. Effects of Tat on Presynaptic AMPA/Kainate Receptors344
  • VI. Effects of Tat on Presynaptic NMDA Receptors344
  • VII. Effects of Tat on Presynaptic Metabotropic Glutamate Receptors348
  • VIII. Specie Specificity of Tat-Mediated Effects and Amino Acid Sequences Involved352
  • IX. Conclusions352
  • Acknowledgments353
  • References353
  • Chapter 19: Evidence to Implicate Early Modulation of Interleukin-1beta Expression in the Neuroprote357
  • I. Introduction358
  • II. Methods360
  • A. Focal Cerebral Ischemia and Drug Treatments360
  • B. Neuropathology and Quantification of Ischemic Damage361
  • C. Subcellular Fractionation361
  • D. Western Blotting361
  • E. IL-1 beta ELISA362
  • F. Statistical Analysis362
  • III. Results362
  • IV. Discussion366
  • Acknowledgments368
  • References369
  • Chapter 20: A Role for Brain Cyclooxygenase-2 and Prostaglandin-E2 in Migraine: Effects of Nitroglyc373
  • I. Introduction374
  • II. Materials and Methods375
  • A. COX-2 Western Blotting375
  • B. PGE2 Assay375
  • III. Results376
  • A. Western Blotting Analysis376
  • B. ELISA Assays377
  • IV. Discussion377
  • Acknowledgments380
  • References380
  • Chapter 21: The Blockade of K+-ATP Channels has Neuroprotective Effects in an In Vitro Model of Brai383
  • I. Introduction384
  • II. Materials and Methods385
  • A. Brain Slice Preparation and Electrophysiology385
  • B. Extracellular Recordings385
  • C. Morphological Studies386
  • D. Drug Application386
  • E. Statistical Analysis386
  • III. Results387
  • A. The Effect of Different Time Courses OGD Application on fEPSP387
  • B. Different Effects of Plasmalemmal Versus Mitochondrial K+-ATP Channel Blockers on the Irreversibl388
  • C. Actions of the K+-ATP Channel Blockers on the Morphological Modifications Induced by In Vitro Isc389
  • IV. Discussion391
  • Acknowledgments393
  • References393
  • Chapter 22: Retinal Damage Caused by High Intraocular Pressure-Induced Transient Ischemia is Prevent397
  • I. Introduction398
  • II. Materials and Methods398
  • A. Ischemia Model398
  • B. Microdialysis399
  • C. Morphometric Analysis399
  • D. Drug Application400
  • E. Statistical Analysis400
  • III. Results400
  • A. CoQ10 Minimizes Glutamate Increase Induced by Ischemia/Reperfusion400
  • B. CoQ10 Affords Neuroprotection Against Cell Loss Yielded by Ischemia/Reperfusion in the RGC Layer401
  • IV. Discussion403
  • Acknowledgments405
  • References405
  • Chapter 23: Evidence Implicating Matrix Metalloproteinases in the Mechanism Underlying Accumulation407
  • I. Introduction408
  • II. Materials and Methods409
  • A. Drugs409
  • B. Subjects410
  • C. Neuropathology410
  • D. IL-1beta ELISA410
  • E. Gel Zymography411
  • F. Fluorimetric Caspase-1 Activity Assay412
  • G. Statistical Analysis412
  • III. Results412
  • IV. Discussion416
  • Acknowledgments418
  • References418
  • Chapter 24: Neuroprotective Effect of Nitroglycerin in a Rodent Model of Ischemic Stroke: Evaluation423
  • I. Introduction424
  • II. Materials and Methods425
  • A. Focal Cerebral Ischemia425
  • B. Neuropathology and Quantification of Ischemic Damage426
  • C. Western Blotting Analyses426
  • D. Statistical Analysis427
  • III. Results427
  • A. Effect of NTG on Infarct Volume427
  • B. Effect of NTG on Bcl-2 Protein Expression427
  • IV. Discussion428
  • Acknowledgments432
  • References432
  • Index437
  • Contents of Recent Volumes451
Book details
  • Vendor Elsevier S & T
  • SKU 9780123739896
  • ISBN-13 9780080550565
  • Author Bagetta, Giacinto
  • Category Medical
  • Subject Neuroscience

Do you have questions about this book?

Ask an expert!

Neuroinflammation has been implicated recently in the pathogenesis of many neurodegenerative diseases. The cross-talk between neurons and non-neuronal cells seems to be a critical step in the progression of neurodegeneration and molecules that have a beneficial role may turn into harmful players. Thus, matrix metalloproteinases (MMPs), which are involved in axonal growth and regeneration as well as synaptic plasticity, may also have detrimental effects. Recent evidence has linked MMPs to conditions like ischemia, multiple sclerosis, Alzheimer's disease and suggested that, together with their role in the degradation of extracellular macromolecules, MMPs could work as important signalling molecules from injured neurons to the microglia.
Thus, MMP-3 has been shown to induce the release of pro-inflammatory cytokines from microglia via activation of ERK and NF-kB-dependent pathways. Increasing evidence highlights the importance of a balanced cross-talk between neurons and non-neuronal cells and indicates that the presence of reactive astrocytes, the activation of microglia and the release of inflammatory mediators may contribute to the progression of many central nervous system disorders, independently of the nature of the primary pathogenic event. However, many aspects still remain controversial and much more effort is needed to understand the role of neuroinflammatory mediators and processes in these conditions.
This volume brings together renowned, international scientists to discuss current knowledge and views on the mechanisms of neuroinflammation, on its role in the context of different neurodegenerative diseases (i.e. Alzheimer's, prion disease, HIV-associated dementia, multiple sclerosis, pain) and on the potential approaches for future therapeutic strategies.